Pharmaresearch Bio파마리서치바이오
217950 · KONEX · ₩217950 · 파마리서치바이오
- Market cap
- ₩122B
- Enterprise value
- ₩113B
- P/E
- 9.9×
- P/B
- 2.1×
- Dividend yield
- 0.0%
- ROE
- 21.4%
- Net margin
- 39.7%
Trailing 12 months from filed financial statements, as of FY 2025. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−21.9% from the high
₩25,000Today: ₩28,000 – ₩29,450₩37,450
Returns
- 1W+1.6%
- 1M+1.9%
- 3M−6.3%
- 6M−20.0%
- YTD−7.4%
- 1Y−5.6%
- Volume today
- 404
- 1.9× the 20-day average
- Traded today
- ₩11M
- Listed shares
- 4,183,240
- EPS (12 months)
- ₩2,947
- Earnings yield 10.1%
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 54: heavy trading.
- SentimentMixedNews: Routine ownership filings with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.9% over the last month; the price is above its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Pharmaresearch Bio stock overview
Pharmaresearch Bio (파마리서치바이오, KRX: 217950) is listed on KONEX, in the Biotech & Pharma sector. The company is a specialized pharmaceutical firm focused on researching and developing botulinum toxin prescription drugs, and it manufactures these products in its dedicated botulinum toxin facility. Its shares closed at ₩29,250 on Oct 30, 2026, up 0.17% on the day, giving it a market value of ₩122B.
Key facts
- Market cap
- ₩122B
- Sector
- Biotech & Pharma
- Latest price change
- +0.17%
- As of
- Oct 30, 2026
- Main business
- The company is a specialized pharmaceutical firm focused on researching and developing botulinum toxin prescription drugs, and it manufactures these products in its dedicated botulinum toxin facility.
Quick answers about Pharmaresearch Bio
- What does Pharmaresearch Bio do?
- The company is a specialized pharmaceutical firm focused on researching and developing botulinum toxin prescription drugs, and it manufactures these products in its dedicated botulinum toxin facility. Its main product is Rientox, which received Korean marketing approval in February 2024 and is sold mainly overseas through its parent company, Pharmaris Research, with nearly all revenue coming from exports. The company is aiming to enter the facial aesthetics market, leveraging its parent's aesthetic product lineup.
- What is the market cap of Pharmaresearch Bio?
- The market capitalisation of Pharmaresearch Bio was ₩122B at the close on Oct 30, 2026.
- Who are the largest shareholders of Pharmaresearch Bio?
- According to the latest official filings, the largest reported holders are Pharmaresearch (62.02%, as of Oct 29, 2026); Shinhan Capital (5.60%, as of Mar 4, 2026).
- When is the next earnings report from Pharmaresearch Bio?
- Korean companies rarely announce results dates in advance. Based on when Pharmaresearch Bio filed the same report in past years, its next annual results is expected between Mar 15, 2027 and Mar 19, 2027.
Company profile
The company is a specialized pharmaceutical firm focused on researching and developing botulinum toxin prescription drugs, and it manufactures these products in its dedicated botulinum toxin facility. Its main product is Rientox, which received Korean marketing approval in February 2024 and is sold mainly overseas through its parent company, Pharmaris Research, with nearly all revenue coming from exports. The company is aiming to enter the facial aesthetics market, leveraging its parent's aesthetic product lineup.
Written by AI from the company's latest annual report.
- Korean name
- 파마리서치바이오
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 백승걸, 원치엽 (각자대표)
- Founded
- Oct 2009
- Listed
- Nov 2015
- Listed shares
- 4,183,240
- Fiscal year ends
- Month 12
- Website
- www.pr-bio.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Insider shareholding reportOct 29, 2026
- 5%+ holding reportOct 29, 2026
- Exercise of Conversion Rights (4th Round)Oct 22, 2026
- Investor relations (IR) eventOct 6, 2026
- Investor relations (IR) eventSep 17, 2026
Titles in Korean until English translations are added.
Also known as: Pharmaresearch Bio / 파마리서치바이오 / 217950 / KRX:217950
Source: KRX statistical information